Kiniksa Pharmaceuticals (NASDAQ:KNSA) announced its earnings results on Thursday. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.03, Fidelity Earnings reports.
KNSA traded up $1.21 during trading on Friday, hitting $21.34. The stock had a trading volume of 1,328 shares, compared to its average volume of 64,905. Kiniksa Pharmaceuticals has a 12 month low of $13.04 and a 12 month high of $32.88.
Several research analysts recently commented on the stock. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, September 11th. JMP Securities lifted their target price on shares of Kiniksa Pharmaceuticals from $33.00 to $44.00 and gave the stock an “outperform” rating in a report on Monday, September 17th.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
See Also: Intrinsic Value and Stock Selection
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.